Focused Ultrasound Helps Release Neurodegenerative Disorder Biomarkers
A noninvasive, focused-ultrasound-mediated liquid biopsy could help facilitate diagnosis of neurodegenerative disorders.
A noninvasive, focused-ultrasound-mediated liquid biopsy could help facilitate diagnosis of neurodegenerative disorders.
Researchers have discovered a correlation between Piwi-interacting RNA and brain inflammation, which will lead to new diagnostic techniques.
Researchers identified a biomarker that can help physicians diagnose Alzheimer’s earlier, as patients transition to cognitive impairment.
It is well established that APOE4, a variant of the apolipoprotein E gene, carries a strong risk for Alzheimer’s disease.
Read MoreResearch shows how large-scale, sensor-based health monitoring can address age-related diseases and health problems that are discovered late.
Read MoreA new study identified multiple new risk genes for Alzheimer’s disease and a rare, related brain disorder through new testing methods.
Read MoreThe FDA granted Roche Breakthrough Device Designation for its Elecsys Amyloid Plasma Panel, designed to enable earlier Alzheimer’s detection.
Read MoreA new, free, online, clinician-administered tool could greatly increase the likelihood of early of primary progressive aphasia detection.
Read MoreMany neurodegenerative diseases, like Alzheimer’s, have been attributed to misfolding of proteins and peptides.
Read MoreAn immuno-infrared sensor can identify signs of Alzheimer’s in the blood up to 17 years before the first clinical symptoms appear.
Read MoreClinical studies have demonstrated a strong association between Alzheimer’s disease (AD) and postoperative delirium.
Read MoreA relatively unstudied protein associated with neurodegeneration may better diagnose and treat Alzheimer’s disease.
Read MoreResearchers have successfully developed a biomarker that will enable Parkinson’s to be rapidly and inexpensively diagnosed via liquid biopsy.
Read MoreMore research is needed regarding blood tests for Alzheimer’s disease before the tests are routinely used in the clinical diagnostic setting.
Read MoreThe Lumipulse G β-Amyloid Ratio (1-42/1-40) in vitro diagnostic is an FDA-authorized test to aid in the assessment of Alzheimer’s disease.
Read MoreA clinical trial is testing a plant-based alternative to hormone therapy to reduce menopausal symptoms and the risk of Alzheimer’s in women.
Read MoreResearch has identified a blood biomarker that could help identify people with the earliest signs of dementia, before the onset of symptoms.
Read MoreResearchers at Albert Einstein College of Medicine have been awarded a $4.2 million NIH grant to detect behavioral markers for Alzheimer’s.
Read More